Aclaris Therapeutics vs Dianthus Therapeutics
ACRS and DNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and DNTH compare
Dianthus Therapeutics is the larger company, worth 8.8 times as much as Aclaris Therapeutics ($5.2B against $589M).
Dianthus Therapeutics scores higher on the StockData Score (7 against 6 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | DNTH |
|---|---|---|
| Size and price | ||
| Market cap | $589M | $5.2B |
| Share price | $4.00 | $92.48 |
| Change, 1 year | 73.9% | 156% |
| Change, 5 years | −71.0% | −13.6% |
| Beta (5Y) | 1.14 | 1.44 |
| Employees | 73 | 92 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 92.0× | – |
| P/B | 3.5× (better) | 4.2× |
| FCF yield | −12.8% | – |
| Growth | ||
| Revenue growth (TTM) | −59.3% | – |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% | – |
| Net margin | −1244% | – |
| FCF margin | −1177% | – |
| Return on equity | −55.5% | −22.6% (better) |
| Return on invested capital | – | −22.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.09 | 30.02 (better) |
| Altman Z-score | −0.30 | 88.77 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −0.01% |
| Shareholder yield | 0.00% (better) | −0.01% |
| Ownership | ||
| Held by institutions | 82.3% | 118% |
| Held by insiders | 13.3% | 9.1% |
| Insider net buying, 12 months | −$1.4M (better) | −$63.8M |
| Short interest, % of float | 9.1% | 18.2% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.